Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132784 | 1.00 | ZDHHC7 (0.50) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL2251886 | 1.00 | ZDHHC7 (0.50) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL7332699 | 1.00 | ZDHHC7 (0.50) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL4846262 | 1.00 | ZDHHC7 (0.50) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL628899 | 0.97 | — | — | |
| SCHEMBL628561 | 0.90 | — | — | |
| SCHEMBL429616 | 0.78 | — | — | |
| SCHEMBL7336733 | 0.78 | ZDHHC7 (0.44) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL7335020 | 0.78 | ZDHHC7 (0.44) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL7331842 | 0.78 | ZDHHC7 (0.44) | ZDHHC7LCKPPARDZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | claimed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | claimed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | claimed |
| US-7375081-B2 | Therapeutic combination of a pneumocandin derivative and an antifungal agent | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7112565-B2 | Stabilized pharmaceutical composition in lyophilized form | ASTELLAS PHARMA INC. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050124536-A1 | Antifungal combination use | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-6232290-B1 | FUNGICIDES AGAINST PNEUMOCYSTIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| WO-2001002002-A1 | STABILIZED PHARMACEUTICAL COMPOSITION IN LYOPHILIZED FORM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000072865-A2 | ANTIFUNGAL COMBINATION USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
| EP-1053247-A1 | ANTIFUNGAL CYCLOHEXAPEPTIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
| US-6107458-A | FUNGICIDE WHICH IS BETA-1,3-GLYCAN SYNTHASE INHIBITOR; FOR PROPHYLAXIS AND TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS LIKE PNEUMONIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| WO-1999040108-A1 | NEW COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-12 | — | — | WO | disclosed |
| EP-0788511-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996011210-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | ZDHHC7 4505/4885LCK 3701/4885PPARD 4436/4885 |
| US-20050124536-A1 | Antifungal combination use | ERG28, MAN2A1, ERP44 | ZDHHC7 2942/4885LCK 3973/4885PPARD 4492/4885 |
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | ZDHHC7 3079/4885LCK 4822/4885PPARD 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.